Society of Hematologic Oncology (SOHO) 2021

Categorized Hematologic Response To Pegcetacoplan In Patients With Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analysis Of Data From Phase 1b (PADDOCK) And Phase 2a (PALOMINO) Trials

Access Resources

Efficacy And Safety At 48 Weeks Of Pegcetacoplan In Adult Paroxysmal Nocturnal Hemoglobinuria Patients With Suboptimal Response To Prior Eculizumab Treatment

Access Resources

Injection Site Reactions At Week 48 In The Randomized Phase 3 PEGASUS Trial Of Pegcetacoplan Compared To Eculizumab For Individuals With Paroxysmal Nocturnal Hemoglobinuria

Access Resources

Management Of Acute Hemolytic Events In Paroxysmal Nocturnal Hemoglobinuria Patients Taking Pegcetacoplan

Access Resources

Patients With Improved Clinical Disease Parameters Also Display Improved Fatigue Following Pegcetacoplan Treatment In Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analyses From The PEGASUS Trial At Week 48

Access Resources

Back to Conference Resources

PNH Congress Presentations

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.